Results 1 to 10 of about 4,245 (206)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements. [PDF]

Cancers (Basel), 2023
Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells distributed throughout the human body. With an increasing incidence over the past few decades, they represent a highly heterogeneous group of neoplasms, mostly expressing somatostatin receptors (SSTRs) on their cell surface. Peptide receptor radionuclide therapy (PRRT) has
Merola E, Grana CM.
europepmc   +6 more sources

Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Rationale: Evaluating the long-term safety and efficacy of peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumors (mNETs) who have undergone prior bland hepatic transarterial embolization (TAE). Methods: Retrospective review of mNET patients who received PRRT with 177Lu-DOTATATE between 4/2018 and 02/2022 with ...
Alayli A, Ngo H, Sikaria D, Ahmed A, Salloum E, Strosberg JR, Al-Toubah TE, Kis B, Haider M, El-Haddad G.   +9 more
europepmc   +5 more sources

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. [PDF]

J Clin Med, 2021
Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are 90Y-DOTATOC and 177Lu-DOTATATE.
Camus B, Cottereau AS, Palmieri LJ, Dermine S, Tenenbaum F, Brezault C, Coriat R.   +6 more
europepmc   +5 more sources

Combination Therapies with PRRT

Pharmaceuticals, 2021
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive.
Anna Yordanova, Hojjat Ahmadzadehfar
doaj   +2 more sources

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

Diagnostics, 2020
The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival.
Virginia Liberini, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, Désirée Deandreis   +10 more
doaj   +3 more sources

Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs). [PDF]

Theranostics
Rationale: Peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumors (NETs) has been explored for more than two decades, but there are only limited data on the treatment of NETs of unknown primary site (CUP-NETs). This study aimed to analyze the long-term outcome, efficacy, and safety of PRRT in patients with CUP-NETs ...
Baum RP, Wang P, Jakobsson V, Zhao T, Schuchardt C, Khong PL, Zhang J.   +6 more
europepmc   +3 more sources

Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT). [PDF]

EJNMMI Phys, 2018
Peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE is an effective treatment of neuroendocrine tumors (NETs). After each cycle of treatment, patient dosimetry evaluates the radiation dose to the risk organs, kidneys, and bone marrow, the most radiosensitive tissues.
Chicheportiche A, Artoul F, Schwartz A, Grozinsky-Glasberg S, Meirovitz A, Gross DJ, Godefroy J.   +6 more
europepmc   +5 more sources

A case report of enduring benefit of sequential PRRT in malignant insulinoma [PDF]

EJNMMI Reports
We report the case of a 62-year-old woman diagnosed in 2015 with de novo metastatic malignant insulinoma. She presented severe hypoglycemia and was initially treated with somatostatin analogs, chemotherapy (capecitabine-temozolomide), and diazoxide, but ...
Cristina-An Wang Zhang, Natacha Driessens, Magdalena Mileva, Amélie Deleporte, Patrick Flamen, Ioannis Karfis   +5 more
doaj   +2 more sources

Use of PRRT and osilodrostat for ectopic Cushing syndrome secondary to thymic neuroendocrine neoplasm [PDF]

Endocrinology, Diabetes & Metabolism Case Reports
We present a case of recurrent thymic neuroendocrine neoplasm (NEN) in a 43-year-old male, who developed ectopic Cushing syndrome (CS), 8 years after his initial diagnosis.
Monica Majumder, Stephen Clarke, Elizabeth Bernard, Venessa H M Tsang   +3 more
doaj   +2 more sources

Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

Journal of Pancreatology, 2023
The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of 68Ga-DOTATATE and 177Lu-DOTATATE. However, many aspects are still under discussion.
Wenjia Zhu, Meixi Liu, Li Huo
doaj   +1 more source